A 52-week, Multicenter, Randomized, Double-blind, Double-dummy, Parallel-group, Placebo-controlled Study of Fevipiprant Once Daily Plus Standard-of-care (SoC) for Reduction of Systemic Corticosteroids (Oral and Parenteral) Use in Patients With Severe Asthma
Phase of Trial: Phase III
Latest Information Update: 24 Sep 2019
Price : $35 *
At a glance
- Drugs Fevipiprant (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 04 Jun 2019 Planned End Date changed from 27 May 2021 to 31 May 2021.
- 04 Jun 2019 Planned primary completion date changed from 27 May 2021 to 31 May 2021.
- 04 Jun 2019 Status changed from not yet recruiting to recruiting.